Parexel to provide trial services for n-Lorem’s nano-rare disease efforts

Parexel and the n-Lorem Foundation have teamed up to encourage the development of treatments for “nano-rare” diseases.

The partnership – financial terms of which were not provided – will see Parexel support n-Lorem’s efforts to discover and provide experimental antisense oligonucleotide (ASO) medicines for patients with nano-rare diseases - those impacting one to 30 people.

n-Lorem CEO Stanley Crooke cited Parexel’s expertise in rare diseases – the CRO has managed approximately 400 rare disease clinical studies over the past five years that contributed to 17 FDA drug approvals – as a key factor.

“We are pleased to be partnering with Parexel, an organization with extensive rare disease expertise that is an expert in managing clinical trials. Parexel will provide the necessary systems to assure that each patient’s natural history and clinical studies are well managed.”

At present, n-Lorem has over 50 nano-rare patients and each requires both an individual natural history study and a clinical study.

Crooke said, “This collaboration exemplifies Parexel’s commitment to nano-rare patients, who present insurmountable challenges to the current healthcare systems.

“Together with our partners and generous donors, n-Lorem is addressing these challenges one nano-rare patient at a time.”

Sarah Glass, n-Lorem’s chief development officer, cited the financial benefits of partnering with Parexel is key.

“n-Lorem is a very nimble organization limited only in our funding and resources. Partnering with Parexel will allow us to expand our clinical research infrastructure, broadening access to n-Lorem for nano-rare patients.”

She added that Parexel’s medical, regulatory and real-world data experts will translate into more robust and supportive clinical research at n-Lorem.

n-Lorem’s partnership model has seen it team up with various financial backers, drug developers and manufacturers over the past few years.

In 2020, for example, it teamed up with the Korea Institute of Toxicology (KIT) – a government-funded research institute that evaluates the safety of medicine.

Under the deal KIT will provides support for pre-clinical toxicity studies which, according to n-Lorem, are the costliest component in the process of providing experimental ASO therapies to patients.

Image: Stock Photo Secrets